BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Huguet JM, Lobo M, Labrador JM, Boix C, Albert C, Ferrer-Barceló L, Durá AB, Suárez P, Iranzo I, Gil-Raga M, Burgos CB, Sempere J. Diagnostic-therapeutic management of bile duct cancer. World J Clin Cases 2019; 7(14): 1732-1752 [PMID: 31417920 DOI: 10.12998/wjcc.v7.i14.1732] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
Number Citing Articles
1 Abou-alfa GK, Bibeau K, Schultz N, Yaqubie A, Millang B, Ren H, Féliz L. Effect of FGFR2 Alterations on Overall and Progression-Free Survival in Patients Receiving Systemic Therapy for Intrahepatic Cholangiocarcinoma. Targ Oncol. [DOI: 10.1007/s11523-022-00906-w] [Reference Citation Analysis]
2 Javle M, Lee S, Azad NS, Borad MJ, Kate Kelley R, Sivaraman S, Teschemaker A, Chopra I, Janjan N, Parasuraman S, Bekaii-Saab TS. Temporal Changes in Cholangiocarcinoma Incidence and Mortality in the United States from 2001 to 2017. Oncologist 2022:oyac150. [PMID: 35972334 DOI: 10.1093/oncolo/oyac150] [Reference Citation Analysis]
3 Jung JH, Yoon SJ, Lee OJ, Shin SH, Han IW, Heo JS. Surgical outcomes and prognostic factors of distal common bile duct adenocarcinoma: chronological analysis in a single high-volume institutional experience. BMC Surg 2022;22:258. [PMID: 35787702 DOI: 10.1186/s12893-022-01649-1] [Reference Citation Analysis]
4 Ioffe D, Phull P, Dotan E. Optimal Management of Patients with Advanced or Metastatic Cholangiocarcinoma: An Evidence-Based Review. Cancer Manag Res 2021;13:8085-98. [PMID: 34737637 DOI: 10.2147/CMAR.S276104] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Pham NA, Radulovich N, Ibrahimov E, Martins-Filho SN, Li Q, Pintilie M, Weiss J, Raghavan V, Cabanero M, Denroche RE, Wilson JM, Metran-Nascente C, Borgida A, Hutchinson S, Dodd A, Begora M, Chadwick D, Serra S, Knox JJ, Gallinger S, Hedley DW, Muthuswamy L, Tsao MS. Patient-derived tumor xenograft and organoid models established from resected pancreatic, duodenal and biliary cancers. Sci Rep 2021;11:10619. [PMID: 34011980 DOI: 10.1038/s41598-021-90049-1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Darbà J, Marsà A. Analysis of hospital incidence and direct medical costs of intrahepatic cholangiocarcinoma in Spain (2000-2018). Expert Rev Pharmacoecon Outcomes Res 2021;21:425-31. [PMID: 33161795 DOI: 10.1080/14737167.2021.1842201] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
7 Mazzoni F, Petreni P, Vasile E, Panebianco M, Casadei-Gardini A, Negri F, Lunghi A, Pillozzi S, Vivaldi C, Gervasi E, Frassineti GL, Messerini L, Jocollé G, Bisagni A, Antonuzzo L, Rossi G. ROS1 rearrangements are uncommon in biliary tract cancers. Oncol Lett 2020;20:316. [PMID: 33133252 DOI: 10.3892/ol.2020.12179] [Reference Citation Analysis]
8 Bekaii-Saab TS, Valle JW, Van Cutsem E, Rimassa L, Furuse J, Ioka T, Melisi D, Macarulla T, Bridgewater J, Wasan H, Borad MJ, Abou-Alfa GK, Jiang P, Lihou CF, Zhen H, Asatiani E, Féliz L, Vogel A. FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with FGFR2 rearrangements. Future Oncol 2020;16:2385-99. [PMID: 32677452 DOI: 10.2217/fon-2020-0429] [Cited by in Crossref: 13] [Cited by in F6Publishing: 46] [Article Influence: 6.5] [Reference Citation Analysis]
9 Zheng J, Yao S. [68Ga]Ga-DOTA-FAPI-04 and [18F] FDG PET/CT for the diagnosis of primary and metastatic lesions in patients with hepatic cancer. Eur J Nucl Med Mol Imaging 2020;47:2078-9. [DOI: 10.1007/s00259-020-04847-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]